Annals of Surgical Oncology

, Volume 19, Issue 6, pp 1790–1799 | Cite as

Prognostication of Soft Tissue Sarcomas Based on Chromosome 17q Gene and Protein Status: Evaluation of TOP2A, HER-2/neu, and Survivin

  • Isabela Werneck da Cunha
  • Louise De Brot
  • Kátia Cândido Carvalho
  • Rafael Malagoli Rocha
  • José Humberto Fregnani
  • Roberto Falzoni
  • Fábio de Oliveira Ferreira
  • Samuel Aguiar Júnior
  • Ademar Lopes
  • Nair Hideko Muto
  • Luiz F. L. Reis
  • Fernando Augusto Soares
  • José Vassallo
Bone and Soft Tissue Sarcomas

Abstract

Background

Topoisomerase 2 alpha (TOP2A), HER-2/neu, and survivin are genes that lie on chromosome 17 and correlate with the prognosis and prediction of target-driven therapy against tumors. In a previous study, we showed that TOP2A transcripts levels were significantly higher in soft tissue sarcomas (STS) than in benign tumors and desmoid-type fibromatoses (FM). Because these genes have been insufficiently examined in STS, we aimed to identify alterations in TOP2A and HER-2 expression by fluorescent in situ hybridization and immunohistochemistry, as well as that of survivin, and correlate them with clinicopathologic findings to assess their prognostic value.

Methods

Eighteen FM and 244 STS were included. Fluorescent in situ hybridization and immunohistochemistry were performed on a tissue microarray.

Results

TOP2A and survivin were more highly expressed in sarcomas than in FM. TOP2A was an independent predictor of an unfavorable prognosis; it was combined with formerly established prognostic factors (primarily histologic grade and tumor size at diagnosis) to create a prognostic index that evaluated overall survival. Gene amplification/polysomy (13%) did not correlate with protein overexpression. Survivin and HER-2 expression were not associated with patient outcomes.

Conclusions

These findings might become valuable in the management of patients with STS and possibly in the prospective evaluation of responses to new target-driven therapies.

Keywords

Sarcoma Soft Tissue Sarcoma Synovial Sarcoma Malignant Peripheral Nerve Sheath Tumor Survivin Expression 

Notes

Acknowledgment

This study was supported by FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo, Brazil). J.V. and F.A.S. are researchers of the CNPq (Conselho Nacional do Desenvolvimento Científico, Brazil).

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Lahat G, Tuvin D, Wei C, et al. New perspectives for staging and prognosis of soft tissue sarcoma. Ann Surg Oncol. 2008;15:2739–48.PubMedCrossRefGoogle Scholar
  2. 2.
    Thway K. Pathology of soft tissue sarcomas. Clin Oncol. 2009;21:695–705.CrossRefGoogle Scholar
  3. 3.
    Segal NH, Pavlidis P, Antonescu CR, et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol. 2003;163:691–700.PubMedCrossRefGoogle Scholar
  4. 4.
    Tschoep K, Kohlmann A, Schlemmer M, et al. Gene expression profiling in sarcomas. Crit Rev Oncol Hematol. 2007;63:111–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Skubitz KM, Pambuccian S, Manivel JC, et al. Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med. 2008;6:23.Google Scholar
  6. 6.
    Cunha IW, Carvalho KC, Martins WK, et al. Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol. 2010;3:23–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol. 1993;4:533–43.PubMedGoogle Scholar
  8. 8.
    Burgess DJ, Doles J, Zender L, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA. 2008;105:9053–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Pritchard KI, Messersmith H, Elavathil L, et al. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol. 2008;26:736–44.PubMedCrossRefGoogle Scholar
  10. 10.
    Esteva FJ, Hortobagyi GN. Topoisomerase IIa amplification and anthacycline-based chemotherapy: the jury is still out. J Clin Oncol. 2009;27:3416–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Järvinen TAH, Liu ET. Topoisomerase IIa gene (TOP2A) amplification and deletion in cancer—more common than anticipated. Cytopathology. 2003;14:309–13.PubMedCrossRefGoogle Scholar
  12. 12.
    Järvinen TAH, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIa associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839–47.PubMedCrossRefGoogle Scholar
  13. 13.
    Di Leo A, Isola J. Topoisomerase IIa as a marker predicting the efficacy of anthacyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer. 2003;4:179–86.PubMedCrossRefGoogle Scholar
  14. 14.
    Arriola E, Marchio C, Tan DSP, et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest. 2008;88:491–503.PubMedCrossRefGoogle Scholar
  15. 15.
    O’Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009;101:644–50.PubMedCrossRefGoogle Scholar
  16. 16.
    Pritchard KI. Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthacycline-based adjuvant chemotherapy for breast cancer? J Clin Oncol. 2009;24:3875–6.CrossRefGoogle Scholar
  17. 17.
    Kanta SY, Yamane T, Dobashi Y, et al. Topoisomerase IIa gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol. 2006;37:1333–43.PubMedCrossRefGoogle Scholar
  18. 18.
    Tretiakova M, Turkyilmaz M, Grushko T, et al. Topoisomerase IIa in Wilm’s tumour: gene alterations and immunoexpression. J Clin Pathol. 2006;59:1272–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Al-Kuraya K, Novotny H, Bavi P, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol. 2007;60:768–72.PubMedCrossRefGoogle Scholar
  20. 20.
    Dimov ND, Zynger DL, Luan C, et al. Topoisomerase II alpha expression in testicular germ cell tumors. Urology. 2007;69:955–61.PubMedCrossRefGoogle Scholar
  21. 21.
    Mano MS, Rosa DD, De Azambuja E, et al. The 17q12–q21 amplicon: Her2 and topoisomerase-IIa and their importance to the biology of solid tumours. Cancer Treat Rev. 2007;33:64–77.PubMedCrossRefGoogle Scholar
  22. 22.
    Murphy AJ, Hughes CA, Barrett C, et al. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res. 2007;67:2893–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Berney DM, Stankiewicz E, Adlan AMA, et al. DNA topoisomerase I and IIa expression in penile carcinomas: assessing potential tumour chemosensitivity. BJU Int. 2008;102:1040–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Ferrandina G, Petrillo M, Carbone A, et al. Prognostic role of topoisomerase-IIa in advanced ovarian cancer patients. Br J Cancer. 2008;98:1910–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Liang Z, Zeng X, Gao I, et al. Analysis of EGFR, HER2 and TOP2A gene status and chomosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer. 2008;8:23.CrossRefGoogle Scholar
  26. 26.
    Washiro M, Ohtsuka M, Kimura F, et al. Upregulation of topoisomerase IIa expression in advanced gallbladder carcinoma: a potential chemotherapeutic target. J Cancer Res Clin Oncol. 2008;134:793–801.PubMedCrossRefGoogle Scholar
  27. 27.
    Baiocchi GL, Villanacci V, Rossi E, et al. HER-1/Neu and topoisomerase-IIa expression and genic amplification in pancreatic adenocarcinoma. Dig Dis Sci. 2009;54:2049–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Coss A, Tosetto M, Fox EJ, et al. Increased topoisomerase IIa expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis. Cancer Lett. 2009;276:228–38.PubMedCrossRefGoogle Scholar
  29. 29.
    Maruya S, Shirasaki T, Nagaki T, et al. Differential expression of topoisomerase IIa protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer. 2009;9:72.PubMedCrossRefGoogle Scholar
  30. 30.
    Tsavaris N, Lazaris A, Kosmas C, et al. Topoisomerase I and IIa protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. Cancer Chemother Pharmacol. 2009;64:391–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Wong N, Yeo W, Wong WL, et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 2009;124:644–52.PubMedCrossRefGoogle Scholar
  32. 32.
    Skotheim RI, Kallioniemi A, Bjerkhagen B, et al. Topoisomerase-IIa is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol. 2003;21:4586–91.PubMedCrossRefGoogle Scholar
  33. 33.
    Storlazzi CT, Brekke h, Mandahl N, et al. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. J Pathol. 2006;209:492–500.PubMedCrossRefGoogle Scholar
  34. 34.
    Lévy P, Vidaud D, Leroy K, et al. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type I, based on large-scale real-time RT-PCR. Mol Cancer. 2004;3:20.PubMedCrossRefGoogle Scholar
  35. 35.
    Rudolph P, Kellner U, Chassevent A, et al. Prognostic relevance of a novel proliferation marker, Ki-S11, for soft tissue sarcoma. A multivariate study. Am J Pathol. 1997;150:1997–2007.PubMedGoogle Scholar
  36. 36.
    Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci. 2008;99:1709–14.PubMedCrossRefGoogle Scholar
  38. 38.
    Kappler M, Kotzsch M, Bartel F, et al. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res. 2003;9:1098–104.PubMedGoogle Scholar
  39. 39.
    Taubert H, Heidenreich C, Holzhausen HJ, et al. Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. BMC Cancer. 2010;10:65.PubMedCrossRefGoogle Scholar
  40. 40.
    Yaziji H, Taylor C. Begin at the beginning, with the tissue! The key message underlying the ASCO/CAP Task-force Guideline Recommendations for HER2 testing. Appl Immunohistochem Mol Morphol. 2007;15:239–41.PubMedCrossRefGoogle Scholar
  41. 41.
    Bhargawa R, Lal P, Chen B. HER-2/neu and topoisomerse IIa gene amplification and protein expression in invasive breast carcinomas. Chomogenic in situ hybridization and immunohistochemical analyses. Am J Clin Pathol. 2005;123:889–95.CrossRefGoogle Scholar
  42. 42.
    Durbecq V, Desmed C, Paesmans M, et al. Correlation between topoisomerase-II-alpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol. 2004;25:1473–9.PubMedGoogle Scholar
  43. 43.
    Mueller RE, Parkes RK, Andrulis I, et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chomosomes Cancer. 2004;39:288–97.CrossRefGoogle Scholar
  44. 44.
    Gaumann A, Tews DS, Mentzel T, et al. Expression of drug resistance related protein in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin. Virchows Arch. 2003;442:529–37.PubMedGoogle Scholar
  45. 45.
    Nuciforo PG, Pellegrini C, Fasani R, et al. Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Hum Pathol. 2003;34:639–45.PubMedCrossRefGoogle Scholar
  46. 46.
    Thomas DG, Giordano TJ, Sanders D, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer. 2005;103:830–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Caldas H, Holloway MP, Hall BM, et al. Survivin-directed RNA interference cocktail is a potent suppressor of tumor growth in vivo. J Med Genet. 2006;43:119–28.PubMedCrossRefGoogle Scholar
  48. 48.
    Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis. 2007;28:1133–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Kappler M, Köhler T, Kampf C, et al. Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer (Pred Oncol). 2001;95:360–3.CrossRefGoogle Scholar
  50. 50.
    Würl P, Kappler M, Meye A, et al. Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet. 2002;359:943–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Kappler M, Bache M, Bartel F, et al. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independent of p53. Cancer Gene Ther. 2004;11:186–93.PubMedCrossRefGoogle Scholar
  52. 52.
    Taubert H, Kappler M, Bache M, et al. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcoma patients. Oncogene. 2005;24:5258–61.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Isabela Werneck da Cunha
    • 1
  • Louise De Brot
    • 1
  • Kátia Cândido Carvalho
    • 1
    • 2
  • Rafael Malagoli Rocha
    • 1
  • José Humberto Fregnani
    • 1
    • 3
  • Roberto Falzoni
    • 1
    • 4
  • Fábio de Oliveira Ferreira
    • 1
  • Samuel Aguiar Júnior
    • 1
  • Ademar Lopes
    • 1
  • Nair Hideko Muto
    • 1
  • Luiz F. L. Reis
    • 1
    • 5
  • Fernando Augusto Soares
    • 1
  • José Vassallo
    • 1
    • 6
  1. 1.Hospital do Câncer A. C. Camargo, Fundação Antonio PrudenteSão PauloBrazil
  2. 2.Laboratório de Ginecologia Estrutural e MolecularFaculdade de Medicina da Universidade de São Paulo (USP)São PauloBrazil
  3. 3.Hospital do Câncer de Barretos, São PauloSão PauloBrazil
  4. 4.Hospital das Clínicas da USPSão PauloBrazil
  5. 5.Hospital Sírio LibanêsSão PauloBrazil
  6. 6.Laboratory of Investigative and Molecular Pathology, CIPEDFaculdade de Ciências Médicas da Universidade de Campinas (Unicamp)São PauloBrazil

Personalised recommendations